Table 2.

Combinatorial viability tests to determine the combinatorial index (CI) of Dasatinib (D) combined with mTOR inhibitor Rapamycin (R) or Torin-2 (T) in neuroblastoma (NB) cell line Kelly, IMR-32, and SK-N-BE(2)

NB cell line/mTOR inhibitors	Kelly [CI]	IMR-32 [CI]	SK-N-BE(2) [CI]
Dasatinib/Rapamycin (D+R)	0.23 ± 0.07	0.20 ± 0.12	0.75 ± 0.02
Dasatinib/Torin-2 (D+T)	0.60 ± 0.15	0.17 ± 0.11	1.25 ± 0.11

Note: CI < 0.9 = synergistic; 0.9-1.1 = additive; > 1.1 = antagonistic